INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
0.8941
-0.1359 (-13.19%)
At close: Nov 19, 2026, 4:00 PM EST
0.8975
+0.0034 (0.38%)
After-hours: Nov 19, 2026, 7:51 PM EST
INmune Bio Revenue
In the year 2025, INmune Bio had annual revenue of $50.00K with 257.14% growth. That makes INmune Bio the 46,553rd largest company in the world by revenue and 6,946th in the United States.
Revenue (ttm)
$50.00K
Revenue Growth
+257.14%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
27.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.00K | 36.00K | 257.14% |
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
INMB News
- 6 days ago - INmune Bio price target lowered to $2.50 from $4 at Freedom Broker - TheFly
- 14 days ago - INmune Bio Earnings Call Transcript: Q3 2026 - Transcripts
- 14 days ago - INmune Bio Quarterly report: Q3 2026 - Filings
- 14 days ago - INmune Bio Earnings release: Q3 2026 - Filings
- 14 days ago - INmune Bio reports Q3 EPS (17c), consensus (19c) - TheFly
- 14 days ago - INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 21 days ago - INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th - GlobeNewsWire
- 22 days ago - INmune Bio announces $4.5M registered direct offering - TheFly